Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol Myers (BMY) receives FDA approval for additional data to be added to the label of the heart drug Camzyos.

Bristol Myers (BMY) Gets FDA Nod for Data Addition to Camzyos

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label.

U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label

NextEra Energy

NIKE

Simon Property Group

UnitedHealth Group

One of the oldest and best ways to get leverage for stock trading is to utilize the options markets.

Goldman Sachs Says Traders Should Use Options to Load Up on These 5 ‘Strong Buy' Blue Chips

Bristol-Myers Squibb Company (NYSE:BMY ) Goldman Sachs 44th Annual Global Healthcare Conference June 13, 2023 11:40 AM ET Company Participants Lynelle Hoch - SVP, Global Cell Therapy Franchise Roland Chen - SVP, Cardiovascular Development Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay. Let's get under way.

Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)

Apple

AbbVie

Accenture Plc

Adobe

Agree Realty

Automatic Data Processing

AGCO

Amgen

Amazon

Air Products and Chemicals

Ares Capital

Alexandria Real Estate Equities

ASML Hld

AvalonBay Communities

Broadcom

Booz Allen Hamilton Hld

Brookfield Asset Management

Brookfield Renewable Partners

SPDR Bloomberg 1-3 Month T-Bill ETF

Blackrock Inc

Brookfield Corp

Broadridge Financial

British American Tobacco

Blackstone Group

My passive income stream increased by 25.59% YoY in April 2023 and 40.02% YoY in May 2023, with a year-to-date growth of 29.99%. I have been taking advantage of high yields on money market funds and short-term treasury ETFs, transitioning about 6.5% of my total portfolio value from a 0% yield into a high-yielding position. I have been making selective reinvestments and trades to increase my passive income stream and accelerate my journey towards financial freedom.

Nicholas Ward's Dividend Growth Portfolio: April And May Review

Repotrectinib could be an impactful treatment for patients with a certain type of lung cancer. The indication could haul in $200 million annually for the company in the United States alone.

This Drug Candidate Could Be a Winner for Bristol Myers

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts.

Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts

Bristol-Myers Squibb Company (NYSE:BMY ) Jefferies Healthcare Conference June 8, 2023 9:00 AM ET Company Participants Adam Lenkowsky - Chief Commercialization Officer Conference Call Participants Akash Tewari - Jefferies Akash Tewari All right. Good morning, everyone.

Bristol-Myers Squibb Company (BMY) Presents at Jefferies Healthcare Conference (Transcript)

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023.

Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023

Bristol-Myers Squibb Company (NYSE:BMY ) 2023 Virtual ASCO Investor Event Conference June 6, 2023 8:00 AM ET Company Participants Tim Power - Investor Relations Samit Hirawat - Chief Medical Officer Adam Lenkowsky - Chief Commercialization Officer Lynelle Hoch - Senior Vice President, Cell Therapy Franchise Lead Rosanna Ricafort - Vice President Cell Therapy Clinical Development Lead Conference Call Participants Chris Schott - JPMorgan Carter Gould - Barclays Matt Phipps - William Blair Dane Leone - Raymond James Terence Flynn - Morgan Stanley Steve Scala - TD Cowen Adam Jolly - Wolfe Research Hao Shen - Bank of America Harry Gillis - Berenberg Olivia Brayer - Cantor Tim Power Good morning. This is Tim Power from Bristol-Myers Squibb Investor Relations.

Bristol-Myers Squibb Company (BMY) Presents at 2023 Virtual ASCO Investor Event Conference (Transcript)

Bristol-Myers Squibb Company has seen its share price trend down as investors remain concerned about a loss of exclusivity. The company has a strong portfolio of assets, and it's worked hard to de-risk its growth opportunities, with 2025 revenue expected to be $10-15 billion risked. Bristol-Myers Squibb's revenue growth potential is strong, and with reduced debt, we expect the company will be able to drive substantial shareholder returns.

Bristol-Myers Squibb Weakness Offers Opportunity

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--The collaboration with Bristol Myers Squibb highlights the confidence and recognition that leading industry players have in MEDiC's technology.

MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on Tumor Target Discovery

Bristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer study upon treatment with the combination immunotherapy of Opdivo plus Yervoy.

Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study

Bristol Myers Squibb (BMY) is an undervalued pharmaceutical stock with strong positioning in cardiovascular, oncology, and immunology sectors. BMY has a strong balance sheet, high margins, and a pipeline of newer drugs, making it an attractive long-term investment. BMY stock offers a well-covered 3.5% dividend yield and has a consensus Buy rating from analysts, with an average price target of $79.

Bristol Myers Squibb: Take The Red Pill

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with.

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Gilead Sciences

Pfizer

Bristol Myers Squibb is a biopharmaceutical industry stalwart that pays a high dividend. Gilead Sciences' valuation is cheap, and its dividend continues to grow.

3 Dividend Stocks You Can Buy Without Any Hesitation

Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.

Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?

Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.

Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review

Bristol Myers Squibb is a company in transition. The uncertainty created by its upcoming leadership change and ongoing portfolio churn has kept investors at bay this year.

Is Bristol Myers Squibb a Top Dividend Stock?

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Hold R&D Day on September 14.

Bristol Myers Squibb to Hold R&D Day on September 14

The author identifies Bristol-Myers Squibb as a potentially attractive investment for long-term dividend growth investors, given its current valuation, yield, and conservative dividend growth. BMY's future growth depends on management's ability to execute their strategy to develop new products and make strategic acquisitions to offset potential revenue declines due to loss of exclusivity in key products. Other stocks identified as attractively valued from a historical and future fair value perspective include 3M Company, Qualcomm, and Elevance Health.

High Quality Dividend Growth Near 52-Week Lows: Bristol-Myers Squibb Is A Good Bet

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #17ICML--BMS to Present Late-Breaking Data for Breyanzi in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 ICML.

Bristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant Lymphoma

Bristol Myers Squibb Co. BMY, -1.15% said Tuesday the U.S. Food and Drug Administration has accepted for priority review its application for repotrectinib as a treatment for patients with certain kinds of non-small cell lung cancer. Repotrectinib was the lead experimental drug of Turning Point Therapeutics, which Bristol Myers acquired for $3.8 billion in June of 2022.

Bristol_Myers says FDA has accepted its non-small lung cancer treatment repotrectinib for priority review

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--US FDA Accepts for Priority Review BMS's Application for Repotrectinib.

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.

News for Bristol-Myers Stock (BMY)